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Treatment of renovascular hypertension: One year results of renal
angioplasty. During the ten year period from 1981 to 1991, percutaneous
transluminal renal angioplasty (PTRA) was performed in 180 renal
arteries in 137 patients, where the underlying renovascular disease was
fibromuscular dysplasia (FMD) in 30 patients (22%) and arteriosclerotic
vascular disease (AVD) in 107 (78%). A preinterventional work-up and a
re-evaluation of the patients after one year was designed for the assess-
ment of the clinical, functional and technical outcome. Successful techni-
cal dilatation was achieved in 97% of procedures with FMD patients and
in 82% of procedures with AVD patients. A beneficial effect on the blood
pressure and the renal function was registered in both groups. The overall
cure and improvement rate for hypertension was 86% in the FMD group
and 64% in the AVD group after one year's follow-up. A significant gain
in the total renal function was registered in both groups, the average
increase in glomerular filtration rate being 13% (P < 0.001) for the FMD
group and 11% (P < 0.001) for the AVD group one year after PTRA.
Renal function was improved or unchanged in 89% of FMD patients and
74% of AVD patients. The improvement in renal function was made by
the revascularized kidney. Renal vein renin investigation predicted the
clinical outcome with an excellent diagnostic accuracy as no renin negative
patient became normotensive, and renin positive patients, who did not
turn normotensive, were in almost 90% of the cases affected by technical
failure or restenosis/contralateral stenosis. Thus, the sensitivity of renal
vein renin investigation was 95% and the specificity 75%. The outcome for
patients with hypertension and renal insufficiency was considerably poorer
than for the whole group of patients, with only a 20% success rate for
hypertension, but 50% in this group had increased or unchanged GFR
after intervention. The angiographic one-year follow-up revealed a recur-
rence rate of 6.7% for FMD and 15.1% for AVD. For the entire series of
patients, the incidence of major complications was 5.4%, including one
indirect fatality, while the incidence of minor complications was 5%. In
conclusion, PTRA will cure or improve blood pressure in most patients
with renovascular hypertension, and it preserves and even improves renal
function in these patients. Complications and recurrence are in fact not
very common and PTRA appears be the best first approach in all but ostial
lesions for treatment of renovascular hypertension.
In 1964 the technique of percutaneous transluminal dilatation
was developed by Dotter and Judkins [1], who used co-axial
catheters to produce progressive dilation of stenotic arteries.
Since the introduction of percutaneous transluminal renal angio-
plasty (PTRA) by GrUntzig et a! in 1978 [2] using a balloon
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catheter, this method has become increasingly popular to use in
patients with hypertension due to renal artery stenosis.
Renovascular hypertension (RVH) is not considered to be a
very common disorder. A review of six studies from the last 10
years, four based on population surveys and two based on clinical
patient materials from specialized hypertension units, has re-
vealed that RVH accounts for only about I to 2% of cases of
hypertension [3]. In an ageing population, stenoses of the renal
arteries may be a far more common cause of hypertension and
end-stage renal failure. It is of major importance to identify this
disorder, since medical therapy may be reduced or avoided and
renal function preserved with interventional treatment.
In our Centre PTRA has been performed since 1981. The aim
of this study was to assess the clinical, functional and technical
outcome of this treatment after one year's observation during the
first ten years.
Patients
The suspicion of RVH was raised during the diagnostic work-up
of hypertensive patients mainly with radiorenography, which is a
primary screening method used by the referring practitioners and
specialized hypertensive care units in our catchment area of 1.6
million inhabitants. Patients with angiographically-proven renal
artery stenosis were evaluated for active treatment with surgery or
PTRA and during the decade from 1981 to 1991; 137 patients
were found and treated with 180 PTRAs.
Classification of the underlying vascular disease was done using
radiological signs. The etiology was considered to be fibromuscu-
lar dysplasia in 30 patients and arteriosclerotic vascular disease in
107 patients. Patient data are presented in Table 1.
Methods
Renal angiography
The radiological diagnosis of renal artery stenosis was mostly
established by digital renal subtraction angiography using a Phil-
ips DSI machine with 512 matrix. By the Seldinger technique, a 5F
rachet-shaped pigtail catheter was placed in the aorta and 35 ml
contrast medium (sodium meglumine ioxaglate 160 mgJ/ml, Guer-
bet, Roissy Charles de Gaulle Cedex, France) was injected at a
speed of 25 ml/sec. Three pictures/sec were recorded during the
arterial phase, in the later phase less frequently. Definite docu-
mentation was processed on film through a laser converter.
The stenoses were radiologically classified in the two groups,
FMD or AVD. The radiologic appearance of an arteriosclerotic
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Table 1. Patients treated for fibromuscular dysplasia (FMD) or
arteriosclerotic vascular disease (AVD) with PTRA from 1981
to 1991
FMD
N %
AVD
N %
Total
N
Number of patients 30 22 107 78 137
Number of PTRAs 33 18 147 82 180
PTRAs males/females 13/20 39/61 94/53 64/36 107/73
Age years mean so 43.0 11.6 62.5 8.7 58 12
range 20-64 39-79 20-79
stenosis was classified as ostial, eccentric plaque or hourglass-
shaped, while the appearance of an FMD most frequently com-
prised the typical multiple "beaded" stenosis, viz. multifocal
stenoses alternating with micro-aneurysms of a diameter greater
than the proximal healthy artery. The remaining lumen in the
stenosis was measured in millimeters down to a minimum of 0.5
millimeters and given as a fraction of the ordinary lumen of the
renal artery. The stenoses were classified into four groups accord-
ing to severity on a falling scale: 0 to ¼, >¼ to >½ to ¾ and
>¾ of the ordinary lumen of the open renal artery.
Restenosis was defined as the condition at the one year
angiographic follow-up, where the minimal luminal diameter in
the stenosis was equal to or less than the diameter measured
before PTRA.
Inter..'entional procedure
Alter local anesthesia, the femoral artery was catheterized with
the Seldinger-technique and for convenient vascular access a 7
French introducer was placed in the artery. After aortography
through a 5 French pigtail catheter, selective catheterization of
the renal artery with a 6.6 French long tapered soft shepherd bend
catheter was performed. Through this catheter a guidewire of the
"movable core" type was led into the vessel and passed beyond
the stenosis. The selective catheter was then removed and over
the guidewire a balloon catheter was slid in place for dilatation.
The balloon catheter used was most frequently of the Olberts type
with a diameter varying from 4 to 7 mm. The balloon was inflated
for one minute and then deflated. The procedure was thereafter
repeated once or twice. The balloon catheter and guidewire were
then removed and a pigtail catheter was introduced and placed
proximal to the renal arteries, and renal angiography was per-
formed to evaluate the effect of dilation. The introducer catheter
was removed four hours later, when the effect of heparin had
declined.
Thromboembolic prophylaxis
Two days before PTRA all patients started prophylactic anti-
thrombotic medication with aspirin 500 mg once daily and dipyra-
midol 75 mg three times daily. This regimen was continued until
discharge from hospital. At the moment of inflation of the balloon
a bolus injection of 5000 IU heparin was given i.v. An infusion of
500 ml low molecular dextran per 12 hours was started postoper-
atively.
Renal function
The glomerular filtration rate (GFR) was measured as plasma
clearance of 51Cr-EDTA [4]. In patients with impairment of renal
function with a plasma clearance below 20 ml/min/1 .73 m2 BSA,
GFR was measured using the renal clearance technique [51.
Radiorenography
Before PTRA, radiorenography with '311-hippuran (7 kBq/kg
body wt) as the radiopharmaceutical was performed twice accord-
ing to a standard protocol: the first with the patient dehydrated by
means of a twelve-hour fluid restriction, and the second after
rehydration with 10 ml water/kg body wt during the hour preced-
ing the second registration [6—8]. Characteristic renograms in
patients with renal artery stenosis show: (1) a delayed parenchy-
mal uptake and a difference in time to peak of the renographic
curve with at least one minute delay on the stenotic side; (2) a
delayed excretion rate with preserved washout phase; (3) a
delayed excretion rate without a washout phase (accumulation
curve); (4) the renal failure pattern with a measurable kidney
uptake; or (5) renal failure pattern without a measurable kidney
uptake (blood-background curve). After hydration of the patient,
a difference in time to peak remains but diminishes in patients
with unilateral renal artery stenosis.
After PTRA radiorenography was used to monitor recovery of
renal function and recordings in the hydrated state were obtained
after one to two weeks and six months. Dehydrated and hydrated
renographic studies were performed at the one-year follow-up.
Renin studies
Before PTRA a renin study was undertaken according to a
standardized protocol in an attempt to study the dependence of
renin secretion on clinical results [8, 9]. Briefly, the patients were
admitted to the hospital for four days before the renal vein
catheterization. Antihypertensive drugs known to suppress renin
secretion as well as ACE inhibitors were withheld and blood
pressure was kept under control with other antihypertensive
drugs. The patients received a sodium reduced diet (10 to 25
mmol sodium 24 hr ')for four days before the investigation. The
renal vein catheterizations were performed between 8 and 12 a.m.
on the fifth day with the patient in the supine position after an
overnight fast. Catheters were inserted into a radial artery and
into both renal veins under fluoroscopic control using the
Seldinger technique. The position of the vein catheters was
confirmed by measurement of oxygen saturation and extraction of
para-amino-hippurate (PAH, Merck, Sharpe & Dohme Interna-
tional, Nutley, NJ, USA). Intra-arterial blood pressure was mon-
itored with a pressure transducer (EMT 34; Siemens-Elema,
Solna, Sweden), using a Mingograph 81 (Siemens-Elema). Mean
arterial pressure (MAP) was obtained from electrically damped
curves.
For renin measurements, blood samples were simultaneously
drawn from the radial artery and both renal veins immediately
before, and 5 and 30 minutes after, stimulation of renin secretion
achieved by three minutes of intravenous infusion of 1.25 mg
enalapril. Patients were considered to have a unilaterally-acti-
vated renin system when the secretion index of renin, calculated
from the renin in the renal venous (P) and arterial (P.,) blood
according to [(Pg — Pa)IaI, was 0.5 only in the affected kidney
during baseline or stimulated conditions, and if, at the same time,
baseline arterial renin activity was 2.0 ng X ml X hr or rose
1.5 times from baseline level after the acute stimulation [9].
Plasma renin was measured as renin activity using a radioimmu-
noassay for angiotensin I. In normal human supine subjects on
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unrestricted diet, plasma renin activity is 1.1 0.8 ng X mI' X
hr' with a 95% confidence interval of 0.8 to 1.4 ng X m1' X
hr and an interassay coefficient of variation of 8.8% [10].
Parameters for evaluation of outcome
Three parameters were used: (1) renal angiography to evaluate
the current status of the renal arteries; (2) blood pressure
decrease and need of antihypertensive treatment expressed as
treatment index (TI) according to Delin et a! [11]; and (3) renal
function estimated as 51Cr-EDTA-clearance and '311-hippuran
radiorenography.
Concerning hypertension, the following criteria were used to
define a successful outcome of intervention based on mean
systolic and mean diastolic blood pressure from at least three
measurements on separate days registered with the cuff method
during hospital stay:
(1) A patient was considered cured if PTRA was followed by
normotension, defined as mean diastolic blood pressure (DBP) 
90 mm Hg without treatment one year after intervention.
(2) A patient was considered improved if satisfactory blood
pressure control (mean DBP 95 mm Hg) was maintained with
a 50% reduction of antihypertensive medication or with a mean
DBP reduction of 20 mm Hg with unchanged medication one
year after intervention.
(3) Remaining patients were not improved.
Statistics
All results have been expressed as means SD. Data were
compared with Student's paired t-test (two tailed) and Wilcoxon's
signed rank test for non-parametric data, when appropriate. P <
0.05 was considered a statistically significant difference.
Results
Fibromuscular dysplasia
According to the radiological criteria, 30 patients were classi-
fied as fibromuscular dysplasia (FMD), of whom 29 patients had
unilateral and one patient bilateral disease. Preoperatively, 25
FMD patients (83%) underwent renal vein renin measurements
and all but one patient were renin positive on the subsequently
treated side. In other words, all but one patient had renin-
dependent hypertension.
Blood pressure and treatment index. As shown in Table 2 and
Figure 1, the mean systolic blood pressure for the FMD group
decreased significantly from 151 21 mm Hg to 131 19mm Hg,
and mean diastolic blood pressure decreased from 93 9 mm Hg
to 81 8 mm Hg one year after intervention. Mean treatment
index also decreased from 15.6 before to 7.5 after treatment
(Table 2). Cure of hypertension was observed in 11 patients and
improvement in 13 patients while a negative outcome, persistent
hypertension and unchanged antihypertensive treatment, was
seen in six patients, indicating an overall failure rate of 20%.
However, one of these six patients was renin negative and in one
patient the dilatation was technically unsuccessful, implying that
angioplasty could not be expected to alleviate hypertension in
these two patients. With this consideration, the clinical failure rate
was at most 14% and the success rate 86% (Table 3).
Renal function. Glomerular filtration rate (GFR) for the FMD
group increased significantly from 77.9 26.7 to 87.9 27.4
ml/min/1.73 m2 BSA. Eighty-nine percent of the FMD patients
Table 2. Effect of PTRA on blood pressure, treatment index and renal
function
FMD
N==30
AVD
N=117
Before PTRA
Systolic mm Hg 151 21 167 23
Diastolic mm Hg 93 9 92 10
TI 15.6 8.4 17.6 9.0
GFR ml/min/1.73m2 BSA 77.9 26.7 47.9 23.5
Relative function of 38.6 15.4 39.9 18.6
the affected kidney %
After PTRA
Systolic mm Hg 131 19 150 24
Diastolic mm Hg 81 8 84 8"
TI 7.5 8.1" 13 8.Y'
GFR ml/min/1. 73m2 BSA 87.9 27.4a 53.3 26.9a
Relative function of (10 days) 44.1 10.3" 44.9 16.4"
the affected kidney % (6 months)
(one year)
45.8 10.3"
46.4 10.1"
45.8 19.9a
47.3 19.1'
Before and one year after intervention total renal function was mea-
sured with 51Cr-EDTA clearance and split renal function with 131J..
hippuran radiorenography in patients with fibromuscular dysplasia (FMD)
or arteriosclerotic vascular disease (AVD). TI is treatment index, that is,
sum of scores for antihypertensive drugs; one antihypertensive drug in the
maximum recommended dosage gives a score of 10. Values are given as
mean so; Student's t-test for paired data (two-tailed) and Wilcoxon's
signed rank test for non-parametric data are used for comparisons of data
without normal distribution before versus after PTRA. ap < 0.001
demonstrated an improved or unchanged GFR, while 11% dete-
riorated. Relative and absolute function of the affected kidney
increased significantly from 39 15% to 46 10% and from 29
15 to 40 16 ml/min/1.73 m2 BSA, respectively (P < 0.001;
Table 2). The greatest increase in relative function for a treated
kidney was from 12 to 50% and in absolute function from 19 to 50
ml/min/1.73 m2 BSA.
Before PTRA 27 patients (90%) had abnormal and 3 patients
(10%) normal renographies. Two of these three patients were not
improved after intervention and therefore only one patient can be
considered false negative according to renography.
Radiological outcome. Angiographic findings and technical suc-
cess rates are given in Table 4. Patients with an initially successful
angioplasty could be divided into two groups at the one-year
follow-up: patients with patent vessels 28 of 30 (93.3%) and
patients with restenosis 2 of 30 (6.7%). Of seven patients with >¼
to of the ordinary lumen of the renal artery open, one was
cured, three improved and three had unchanged hypertension.
Only six FMD patients had persistent hypertension at the one-
year follow-up, and among these, one patient was renin negative
and one patient was not successfully dilated and classified as a
technical failure.
Complications. One major complication (embolization to a leg)
was observed, and 4 out of 33 angioplasties (12%) caused minor
complications for the patients. On three occasions spasm of the
renal arteries was registered (Table 5).
Arteriosclerotic vascular disease
According to the radiological criteria, 107 patients were classi-
fied as arteriosclerotic vascular disease (AVD) patients. Seventy-
four patients had unilateral and 33 patients bilateral disease.
Before PTRA 54 AVD patients (50%) underwent renal vein renin
measurements; 43 patients were renin positive and 11 renin
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Table 3. Clinical outcome evaluated by the reduction in blood pressure
one year after intervention in 102 patients with renovascular
hypertension caused by either fibromuscular dysplasia (FMD) or
arteriosclerotic vascular disease (AVD) treated with PTRA
FMD AVD
N % N %
Number of patients 28 100 74 100
Cure 11 39 11 15
Improvement 13 47 36 49
No improvement 4 14 27 36
Overall benefit (cured + improved) 86 47 64
Cure is defined as normotension mean DBP 90 mm Hg without
treatment one year after PTRA. Improvement is mean DBP 95 mm Hg
with 50% reduction in antihypertensive drugs or a reduction of  20 mm
Hg ( 17% of initial value) in mean DBP with unchanged level of
medication one year after PTRA.
Table 4. Technical outcome of 180 PTRAs in 137 patients with
renovascular disease caused by fibromuscular dysplasia (FMD) or
arteriosclerotic vascular disease (AVD) according to angiographic
evaluation peroperatively and one year postoperatively
Number of PTRAs
Technical success
Technical failure
Preoperative angiographic findings
0-1/4 of ordinary lumen
>1/4-1/2 of ordinary lumen
>1/2-3/4 of ordinary lumen
Poststenotic dilatation
Collateral circulation
Drop-outs one year after PTRA
Angiographic findings one year after PTRA
0-1/4 of ordinary lumen
>1/4-1/2 of ordinary lumen
>1/2-3/4 of ordinary lumen
No stenosis
Results of primarily successful PTRAs
Luminal diameter improved
Luminal diameter unimproved
FMD AVDN % N %
33 100
32 97
1 3
147 100
121 82
26 18
16 49
15 45
2 6
30 90
3 10
2 6
90 61
45 31
12 8
125 85
7 5
34 23
31 100
0 0
7 22
8 26
16 52
30
28 93.3
2 6.7
113 100
10 9
17 15
36 32
50 44
86
73 84.9
13 15.1
65 70 75 80 85 90 95 100 105 110 115
Diastolic blood pressure before PTRA, mm Hg
Fig. 1. Comparisons of mean systolic (A) and mean diastolic (B) blood
pressure before and one year after PTRA in 33 FMD patients (P < 0.001).
Circles below the bold diagonal line indicate a decrement in blood
pressure after PTRA.
negative, and thus only 80% of the patients subjected to renin
study had renin-dependent hypertension.
Blood pressure and treatment index. Table 2 and Figure 2 show
that mean systolic blood pressure decreased significantly from 167
23 mm Fig to 150 24 mm Hg, and mean diastolic blood
pressure decreased from 92 10 mm Hg to 84 8 mm Hg. These
results are based on the 117 technically successful angioplasties as
the stenosis was not dilated in 16 and the technical result of
angioplasty was not satisfactory in 13 angioplasties. Mean TI
decreased from 17.6 9.0 to 13.0 8.3 (P < 0.001) one year after
intervention.
Ninety patients were available for evaluation concerning blood
pressure outcome. Cure of hypertension was achieved in 11
patients (12%) and an improvement in 36 patients (40%), viz.
52% of the patients gained benefit from intervention regarding
relief of hypertension.
However, taking into consideration that seven patients in the
clinical failure group were renin negative and nine had a techni-
cally unsuccessful PTRA, the true cure and improvement rate was
at least 64%.
Seventeen patients were not available for follow-up, which
implies a drop-out rate of 16% (17 of 107); two patients began
dialysis therapy, one patient received a renal transplant, three
patients died of other diseases, and eleven patients were lost
either because of unwillingness to participate or change of
residence.
In summary, at least 64% AVD patients with RVH were
improved after PTRA in terms of relief of hypertension.
Renal function. As shown in Table 2 and Figure 3, glomerular
filtration rate for 80 AVD patients increased significantly from
A
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Table 5. Complications observed in 180 angioplasties in 137 patients
treated for renal artery stenosis caused by fibromuscular dysplasia
(FMD) or arteriosclerotic vascular disease (AVD)
FMD
N=33
AVD
N=147
Major complications
Occlusion of the renal artery 3 (one bilateral)
Hemorrhagic anemia 3
Postoperative myocardial infarction 1 (lethal)
Embolization to a leg 1 1
Acute renal failure 1
Total 3% 5.4%
Minor complications
Minor renal infarction 1 1
Perforation of a branch artery 1
Hematoma in the groin I I
Intimal lesion 1
Rupture of the balloon 1 1
Local infection at puncture site 1
Total 12% 3%
47.9 23.5 to 53.3 26.9 ml/min/1.73 m2 BSA. Seventy-four
percent of the AVD patients had an increased or unchanged GFR
while 26% deteriorated. Relative and absolute function of the
affected kidney increased significantly from 39 19% to 47
19% and from 21 12 to 28 13 ml/min/1.73 m2 BSA
respectively (P < 0.001; Table 2). The most conspicuous increase
in relative function for a treated kidney was from 15 to 50% and
in absolute function from 18 to 55 ml/min/1.73 m2 BSA.
Seventy-one (77%) had abnormal and 21(23%) normal renog-
raphies before PTRA. Twenty out of these 21 normal patients
were not improved after intervention and therefore only one
AVD patient can be considered false negative according to
renography.
Radiological outcome. Results are shown in Table 4. PTRA was
performed in the right renal artery in 40% of the patients and in
the left renal artery in 50%. Bilateral intervention was undertaken
in eight patients (5.7%), and intervention on a single or function-
ally single kidney in six patients (4.3%). The radio-morphological
appearance of the stenosis was the hourglass-shaped or localized
circumferential narrowing in 75% of the cases. A localized
eccentric plaque was seen in 12% and an ostial stenosis was
apparent in 11%. Only in three cases (2%) was an attempt made
to dilate an occluded vessel.
An Olberts balloon catheter was used in 89% of the cases, and
in the remaining 11% other types of balloon catheters were
employed. The diameter of the balloon catheter was 6 mm in
49.2% of the dilatations, 5 mm in 30.3%, 7 mm in 13% and 4 mm
in 7.5%.
Technically successful angioplasty was defined as a wider lumi-
nal diameter of the stenotic area as judged from the subsequent
renal angiography. This was achieved in 121 interventional pro-
cedures (82.3%). In six dilatations (4.1%) the stenosis remained
unchanged and in 20 (13.6%) the balloon catheter could not be
manipulated into place in the stenosis.
One hundred and thirteen angiographic re-evaluations were
performed, which implies a drop-out rate of 23%. The preoper-
ative angiographic appearance in 34 drop-out patients showed a
severity of stenosis of 0 to ¼ of the ordinary lumen open in 62%
of the patients, >¼ to of the ordinary lumen open in 29% and
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Fig. 2. Comparisons of mean systolic (A) and mean diastolic (B) blood
pressure before and one year after 90 technically successful PTRAs in A VD
patients (P < 0.001). Circles below the bold diagonal line indicate a
decrement in blood pressure after PTRA.
>½ to ¾ of the ordinary lumen open in 9%, a distribution of the
severity of stenosis which do not diverge from the entire patient
material for AVD.
The results of the re-evaluation of the stenoses in patients with
primary technical success one year later are given in Table 4 and
Figure 4. Patients with an initially successful angioplasty could be
divided into two groups at the one-year follow-up: patients with
patent vessels 73 of 86 (84.9%) and patients with restenosis 13 of
86 (15.1%). However, not all of these treatments failed clinically
as improvement of blood pressure was obtained in 4 out of 13
patients, while it was unchanged in 9 patients.
A
B
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Fig. 3. Comparisons of glomerular filtration rate measured as 51Cr-EDTA-
clearance before and after technically successful PTRA in 26 FMD patients
(A, P < 0.001) and 80AVD patients (B, P <0.001). Circles above the bold
diagonal line indicate an increment in GFR after PTRA.
Eighteen ostial stenoses was registered in this patient series, of
which 13 were successfully dilated and 5 were technical failures.
This means a technical success rate of 72% for ostial stenosis. Of
the 13 successful dilatations, none was cured of hypertension and
only three patients were improved; thus a benefit for this type of
stenotic lesion was only seen in 23%. However, four patients had
an improved GFR and three patients an unchanged GFR; there-
fore a renoprotective effect could be claimed in seven patients
(54%) with ostial stenosis.
Complications. The major complications were as follows: (1)
occlusion of the renal artery in three cases, with bilateral occlusion
in one of these, leading to immediate bypass surgery to save renal
function; (2) hemorrhagic anemia in three cases, and among these
one case followed by acute myocardial infarction with a lethal
outcome; (3) embolization to a leg in one case causing a compart-
ment syndrome, which needed surgical intervention with fas-
ciotomy; (4) acute renal failure in one patient with severe
preoperative renal insufficiency (GFR = 13 ml/min/1.73 m2 BSA).
The rate of major complications was thus 9 out of 147 interven-
tional procedures (6.1%). Five minor complications were ob-
served: one rupture of the balloon without causing damage, one
minor renal infarction, one perforation of a minor branch artery
without symptoms, one inguinal hematoma and one intimal lesion
(Table 5).
Clinical outcome versus renin investigation before PTRA
Twenty-five FMD patients and 54 AVD patients were investi-
gated with renal vein renin measurements. In the first group 24
patients were renin positive and one patient renin negative, and in
the second group 43 patients were renin positive and 11 renin
negative; thus altogether 67 renin positive and 12 renin negative
patients were found. Two renin positive patients were not avail-
able for follow-up. Forty-one of 65 renin positive patients were
cured or improved after PTRA and 24 patients were not im-
proved. However, when evaluating the outcome in these 24
patients at the one-year follow-up there were nine patients with a
technical failure, six with restenosis, three with stenosis in the
contralateral renal artery, two with an ischemic contralateral
kidney, and one patient with a tight renal branch stenosis. Only
three renin positive patients had an unexplained clinical failure
after angioplasty.
Of 12 renin negative patients, one was not available for
follow-up. Only two patients improved, none was cured and nine
patients had persistent hypertension after angioplasty. With these
considerations, the sensitivity of renal vein renin investigation was
95% and the specificity 75% for the prediction of the clinical
outcome after angioplasty.
Outcome for patients with hypertension and renal insufficiency
Twenty-two patients out of the entire patient material (1 with
FMD and 21 with AVD) had impairment of renal function
arbitrarily defined as a glomerular filtration rate 30 mI/mm/I .732 BSA. Twenty successful dilations were performed. At the
one-year follow-up four patients had improved and 16 unchanged
blood pressure, which gives a 20% success rate for relief of
hypertension in this group of patients. However, the effect of
dilation on renal function showed an increase in GFR preopera-
tively from 16.2 7.5 ml/min/1.73 m2 BSA to 20.1 12.0 ml!
min/1.73 m2 BSA one year postoperatively, although this increase
was not statistically significant. Nevertheless, 10 patients, or 50%,
in this group obtained an increased GFR after intervention.
Eight patients had severe renal failure, defined as GFR < 15
mI/mm/i .73 m2 BSA, and of these patients only one showed an
improved blood pressure and two an increased GFR after inter-
vention. One patient went into acute renal failure and four
patients deteriorated to end-stage renal failure and became
dialysis patients (Table 5).
Patients treated with surgery after unsuccessful PTRA
Only six patients went through surgical revascularization later.
Three patients were operated bilaterally, one as an acute opera-
tion and two as elective. Of these three patients one had a
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restenosis on the right side at the angiographic one year follow-up
and the remaining two had no sign of stenosis. Three patients
were operated unilaterally, one patient without success and the
remaining two patients were lost at the one year follow-up.
Discussion
Percutaneous transluminal angioplasty has been used for treat-
ment of vascular obstructive disease for more than a decade.
Previous reports have often focused on either technical or func-
tional aspects. In this study, success of the procedure is based on
an integrated judgment of clinical, functional and technical as-
pects. The clinical assessment comprised evaluation of the relief
of hypertension in terms of reduction of blood pressure and
antihypertensive medication. The functional outcome was as-
sessed in terms of the effect on renal function measured as total
GFR and split renal function with renography, which has not
previously been systematically studied. The technical assessment
included estimation of the initial failure rate, the degree to which
a lesion could be dilated, the frequency of complications and the
patency rate versus the recurrence rate judged by angiographic
one-year follow-up. In fact, few major series with an angiographic
re-evaluation one year after intervention are available [12—15].
Fibromuscular dysplasia
The overall clinical success rate in our series was 86%, with
39% cured and 47% improved. The clinical failure rate in this
series was 14%, which seems to be a higher failure rate compared
to the results in previous studies. However, we used a very strict
definition of improvement [11] compared to many studies, which
may account for some disparities.
The effect of PTRA on renal function has not been thoroughly
elucidated in previous reports where the effect on renal function
has mainly been judged by measurement of serum creatinine
before and after PTRA. We observed a significant increase in
GFR after angioplasty of 13% and have shown that this increment
in renal function is caused by recovery of the stenotic kidney. The
recovery was already evident ten days after angioplasty but a
Fig. 4. Comparison of preoperative and
postoperative angiographic findings one year after
angioplasty in A VD patients. Number of patients
with a compromized lumen of the renal artery
before (N = 147) and one year after (N = 113)
PTRA given as % of the estimated normal
lumen: 0 to 25%, tight stenosis; >25 to 50%,
moderate stenosis; and >50 to 75%: slight
— stenosis. Dark area in bars indicates patients
No stenosis with restenosis at one year follow-up (13
patients; 15% of the primarily successful
PTRAs).
further increase was registered at the one-year follow-up. This
observation may indicate that the function had deteriorated in the
low pressure perfused kidney and recovered with time. In our
series, 89% of the patients with FMD demonstrated improved or
unchanged renal function after PTRA.
The overall technical success rate was 97% and the patency rate
78%, which means that 22% of the patients had residual stenosis
between 50 and 75% at the one-year follow-up. However, the rate
of recurrence of stenosis was estimated to be 6.7%, which is
excellent compared to other recent studies [13, 161. The frequency
of complications in patients with FMD was low, 12% minor
incidents without causing permanent damage or inconvenience to
the patient. Spasm of the renal artery during PTRA may damage
the renal parenchyma and was seen in our series in three
interventional procedures or 1.6%, exclusively in patients with
FMD [17, 181. However, permanent damage was not seen.
Summarizing, the results of angioplasty in FMD patients in our
series are excellent compared with other published results [12, 13,
16, 19—27] and it is of special interest that the renal function had
improved at the one-year follow-up.
Arteriosclerotic vascular disease
When reviewing the literature, it is quite clear that success rates
for AVD patients are more widely scattered than for FMD
patients [12—14, 16, 21, 22, 25—36]. In the present study, we
obtained an overall clinical success rate concerning cure and
improvement of hypertension of 64%, with 15% cured and 49%
improved, which is in fact comparable to other reports.
Likewise, for AVD patients a significant increase in GFR of
11% one year after angioplasty was observed and the increment in
renal function was caused by recovery of the stenotic kidney as
measured with renography. In our series, 74% of the patients with
AVD demonstrated improved or unchanged renal function after
PTRA, an excellent result in this group of patients with chronic
arteriosclerotic vascular disease.
For ostial stenotic lesions, it has been claimed that the feasibil-
ity of performing a permanent luminal expansion is reduced [21].
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As in previous reports [141, we noted a lower technical success
rate of 72% in patients with ostial stenotic lesions and the clinical
outcome was even worse. Only 23% obtained amelioration of
hypertension and none was cured. However, an improved or
unchanged GFR was observed in 7 out of 13 patients.
The overall technical success rate was 82%, which is superior to
the results of several previously published large series. In a study
of 100 patients with atheromatous disease, the technical success
rate was 76.2% for unilateral, 74.1% for bilateral and 67.7% for
solitary cases [36]. In a report from Klinge et al [12] on a material
with 213 interventional procedures, an overall technical success
rate of 80.8% was claimed, but when the patient material was
separated into patients with FMD and AVD, the success rate for
the latter group was only 74%. Although numerous reports have
been published claiming success rates from 56% to 100% [21, 22,
26, 28—31, 34—43], it seems reasonable to consider a technical
success rate around 80% as what can be achieved with angio-
plasty.
The patency rate after one year in our series was 76%, which
leaves 24% with luminal obstruction of > 50%. However, when
comparing the initial angiographic result of technically successful
angioplasty with the conditions after one year, no improvement
was found in 13 out of 86, or 15.1%, a figure that reflects the
recurrence rate within one year. In the study by Klinge et al [12],
which included 115 arteriosclerotic patients, the authors suc-
ceeded in performing angiographic follow-up in 80 patients and
registered recurrence in 14 cases, a recurrence rate of 17.5%.
Considerably higher recurrence rates, at most 42%, have been
reported, albeit early in the era of PTRA and in small series [44].
In a recently published study by Plouin et al, 104 patients were
studied and angiograms obtained before and 8.8 6.0 months
after angioplasty in 92 patients [13]. They found a recurrence rate
of 16%. Therefore, we consider a recurrence rate of at least 15 to
20% within one year should be expected.
Major complications occurred in 9 out of 47, or 6.1% of AVD
patients, surgical intervention being needed in two cases. One
indirect death was registered in our whole material of 137
patients, which means a mortality rate of 0.7%, a number in
accordance with other reported series [12, 18, 44—49]. The
incidence of minor complications was comparatively low, only 5
out of 147, or 3.4% [18, 45—47, 49].
Clinical outcome versus renal vein renin investigation
The normal ratio of renal vein (P) to vena caval (Pa) renin
activity is approximately 1.24 (Pv/a) for each kidney. The
normally exceeds the a because of renal secretion of renin [50].
In patients with renovascular hypertension, circulating renin
originates from the affected kidney, with suppression of renin
secretion in the contralateral kidney. Thus, the affected kidney
will have a Pv/Pa ratio exceeding 1.5 and the contralateral kidney
1.0 or less. In studies that for the most part used a Pv/Pa ratio
(affected to contralateral kidney) of 1.5 or more as the diagnostic
criterion, a sensitivity of only 80% and a specificity of 62% was
reported in a review of 58 studies [51]. However, stimulation of
renin secretion using sodium depletion, diuretics, hydralazine,
nifedipine and captopril can exaggerate the asymmetry of renin
secretion and can improve the sensitivity without compromising
specificity [52].
The specificity can be further improved using measurements of
renin release from each kidney in a non-steady state after acute
stimulation according to Delin et a! [9]. Occasionally, other renal
causes of hypertension, such as renal cysts, pyelonephritis and
ureteral obstruction, can cause asymmetry of renin secretion and
explain a false-positive result [52].
In the present study, a sensitivity of 95% and a specificity of
75% was achieved, demonstrating the excellent diagnostic accu-
racy of renal vein renin determinations, when including measure-
ments in a non-steady state after acute stimulation. The renal vein
renin investigation had a high positive predictive value of 98% and
a good negative predictive value of 82% for the outcome of
PTRA.
Renal insufficiency and hypertension
The effect of revascularization on renal function achieved by
PTRA or surgery has been discussed by many authors. As
reviewed by Kremer Hovinga et al [53], frequencies of improve-
ment of renal function varying between 17% and 100% of the
treated patients have been reported. However, these reports are
only based on measurements of serum creatinine before and at
various time intervals after intervention (19.6 16,6 months) and
often in small patient series. Most interestingly, a significant
increase in GFR was observed one year after angioplasty and the
benefit was noted for the stenotic kidney as measured by ra-
diorenography. Altogether 74% of patients with AVD showed
improved or unchanged renal function after PTRA.
In the present study, of 22 patients with renal insufficiency,
defined as GFR 30 ml/minhl.73 m2 BSA, 20 could be dilated
successfully and an increased or unchanged GFR was in fact
recorded in 50% [54, 55]. In patients with severe renal failure
(GFR < 15 ml/minhl.73 m2 BSA) the results were less encourag-
ing, but nevertheless 25% showed an increased or unchanged
GFR one year after intervention. These data indicate that in
patients with impaired renal function, PTRA has the most benefit
when renal impairment is moderate [56].
General comments
The effects of PTRA on renovascular hypertension compare
favorably to those obtained with surgery when an intensive
follow-up and aggressive reinterventional strategy was advocated
according to the randomized study of Weibull et a! [15] and as
later reviewed by Novick [57]. In many reports, it is not likely that
the patient populations subjected to surgery or PTRA are com-
parable. It seems probable that several patients with AVD treated
with PTRA would never have been accepted as candidates for
reconstructive surgery, as many of these patients carry a major
cardiovascular risk. In fact, after the advent of PTRA surgery of
the renal arteries has been largely abandoned due to the size of
the interventional procedure.
However, renal angioplasty may be considered a safe procedure
only when immediate access to surgical expertise is available and
safe routines for dealing with complications are established. Renal
angioplasty is in comparison with reconstructive surgery definitely
more convenient for the patient, less expensive and less invasive
and requires a shorter hospital stay.
The recurrence rate is very low in FMD and somewhat higher
in AVD, but still considerably lower than the recurrence rates
reported for PTCA [58]. The reason for these diverging results
between renal and coronary angioplasty is not clearly elucidated,
but such factors as smaller vessel diameter in the coronary
circulation, where even minor plaques may be hemodynamically
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deleterious, and numerous bifurcations in the coronary vascular
tree predisposing to a turbulent blood flow causing shear stress in
the vascular wall may be suggested.
Vigorous efforts in treating patients with impending renal
insufficiency should never cease and even in this aspect renal
angioplasty has its natural place in the therapeutic repertoire.
Beneficial effects of revascularization of kidneys living under the
threat of ischemic death were most apparent in patients with
moderate renal impairment but less evident in patients close to
end-stage renal failure, where irreversible damage of the renal
parenchyma is inevitable.
Conclusions
The results of treatment with renal angioplasty in patients with
fibromuscular dysplasia are excellent in terms of relief of hyper-
tension with a cure and improvement rate of 86%. The results in
patients with arteriosclerotic vascular disease are satisfactory
despite a lower rate of relief of hypertension with a cure and
improvement rate of 64%.
Renal angioplasty is technically feasible in 97% of stenoses
caused by fibromuscular dysplasia and in 82% of stenoses caused
by arteriosclerotic vascular disease. A recurrence rate within one
year below 10% was achieved in patients with fibromuscular
dysplasia and 15% in patients with arteriosclerotic vascular dis-
ease.
Renal vein renin investigation predicts the clinical outcome
with an excellent diagnostic accuracy as the sensitivity was 95%
and the specificity 75%.
Renal angioplasty improves renal function in 89% of patients
with fibromuscular dysplasia and in 74% of patients with arterio-
sclerotic vascular disease and in both groups the increment in
renal function was registered for the stenotic kidney one year after
intervention.
Renal angioplasty has the most beneficial effect concerning
improvement of renal function when renal impairment is moder-
ate, which indicates that a remaining renal parenchymal mass may
be possible to preserve.
In conclusion, renal angioplasty appears to be the best first
approach for treatment of renovascular hypertension, whether
caused by fibromuscular dysplastic or arteriosclerotic vascular
disease.
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